BioNTech vs Pfizer: Revenue, Profit and Business Model
BioNTech had ~$3.2B of annual revenue in FY2025 and a net loss of ~$1.3B. Pfizer had $62.6B of annual revenue in FY2025 and $7.8B of net income.
Latest financial snapshot
Financial summary
BioNTech
BioNTech went from a ~$202 million (€179.1 million) net loss in 2019 to ~$11.6 billion (€10.29 billion) of net profit on ~$21.4 billion (€18.98 billion) of revenue in 2021, almost all from Comirnaty. Revenue then fell to ~$19.6 billion (€17.31 billion) in 2022, ~$4.32 billion (€3.82 billion) in 2023 and ~$3.11 billion (€2.75 billion) in 2024, when it posted a ~$752 million (€665.3 million) net loss. FY2025 revenue rose 4.3% to ~$3.24 billion (€2.87 billion) only because BMS collaboration revenue was booked in Q3, while the net loss widened to ~$1.29 billion (€1.14 billion) on ~$2.37 billion (€2.10 billion) of R&D and legal settlement costs. In 2026 the decline resumed: H1 revenue fell to ~$253 million (€223.7 million), the H1 net loss reached ~$1.53 billion (€1.35 billion), and full-year revenue guidance was cut to €1.6-1.9 billion. The cushion is ~$18.8 billion (€16.6 billion) of cash and securities at June 30, 2026, which also funds a $1.0 billion ADS buyback launched in May 2026. BioNTech skyrocketed in value during the global pandemic, maintaining a market valuation generally exceeding $20 billion driven by its mRNA pipeline.
Pfizer
Pfizer revenue rose from $41.7 billion in 2020 to $81.3 billion in 2021 and $101.2 billion in 2022 on Comirnaty and Paxlovid, then fell to $59.6 billion in 2023 as COVID demand collapsed. It recovered to $63.6 billion in 2024 and was $62.6 billion in 2025, with net income of $7.8 billion. In Q2 2026 revenue was $15.0 billion, up 1% operationally, or 5% excluding COVID products, and Pfizer raised the midpoint of its 2026 revenue guidance to $60.5 billion to $62.5 billion with adjusted EPS guidance of $2.80 to $3.00. The roughly $31 billion of debt raised for Seagen in 2023 and an ongoing cost-reduction program shape capital allocation alongside a dividend yield near 6%. Pfizer ranks among the largest pharmaceutical companies in the world, carrying a market valuation typically exceeding $150 billion.
Revenue and profit by year
BioNTech
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | ~$3.2B | ~-$1.3B | -39.6% | +4.3% | Source |
| FY2024 | ~$3.1B | ~-$751.8M | -24.2% | -28.0% | Source |
| FY2023 | ~$4.3B | ~$1.1B | 24.4% | -77.9% | Source |
| FY2022 | ~$19.6B | ~$10.7B | 54.5% | -8.8% | Source |
| FY2021 | ~$21.4B | ~$11.6B | 54.2% | +3834.6% | Source |
| FY2020 | ~$545M | ~$17.2M | 3.2% | +344.1% | Source |
| FY2019 | ~$122.7M | ~-$202.4M | -164.9% | -14.9% | Source |
| FY2018 | ~$144.2M | ~-$54.3M | -37.6% | +107.1% | Source |
| FY2017 | ~$69.6M | ~-$96.8M | -139.1% | — | Source |
Pfizer
| Year | Revenue | Net income | Margin | Growth | Source |
|---|---|---|---|---|---|
| FY2025 | $62.6B | $7.8B | 12.4% | -1.6% | Source |
| FY2024 | $63.6B | $8B | 12.6% | +6.8% | Source |
| FY2023 | $59.6B | $2.1B | 3.6% | -41.1% | Source |
| FY2022 | $101.2B | $31.4B | 31.0% | +24.5% | Source |
| FY2021 | $81.3B | $22B | 27.0% | +95.2% | Source |
| FY2020 | $41.7B | $9.2B | 22.0% | +1.8% | Source |
| FY2019 | $40.9B | $16B | 39.2% | +0.2% | Source |
| FY2018 | $40.8B | $11.2B | 27.3% | -22.3% | Source |
| FY2017 | $52.5B | $21.3B | 40.6% | -0.5% | Source |
| FY2016 | $52.8B | $7.2B | 13.7% | — | Source |
Where the revenue comes from
BioNTech
- COVID-19 vaccine (Comirnaty)
majority of revenue
BioNTech's 50% share of gross profit on Pfizer sales outside Germany, plus direct German sales. Lower demand drove H1 2026 revenue down to ~$253 million (€223.7 million) from ~$501 million (€443.6 million).
- Collaboration and licensing revenue
material, lumpy
Mainly Bristol Myers Squibb payments for pumitamig; BioNTech expects to recognize ~$693 million (€613 million) of BMS collaboration revenue in Q3 2026.
- Government contract and services
small, stable
A pandemic-preparedness contract with the German government and service businesses.
- Future oncology product sales
not yet generating revenue
Depends on approvals for pumitamig, its ADCs and other late-stage candidates.
Pfizer
- Patented medicines
Core revenue
Prescription drugs protected by exclusivity and clinical differentiation.
- Vaccines
Major revenue contributor
Adult, pediatric, pneumococcal, RSV, and COVID-related vaccines.
- Oncology
Strategic growth driver
Cancer medicines, antibody-drug conjugates, and Seagen-related assets.
- Hospital and anti-infective products
Meaningful contributor
Sterile injectables, anti-infectives, and hospital therapies.
- Collaborations and alliances
Supplemental
Co-promoted products and partnered scientific platforms.
Business model and strategy
BioNTech
How it makes money
BioNTech SE operates a biotechnology commercialization and clinical development model, generating revenue through commercial vaccine sales, pharmaceutical partnership profit splits, licensing agreements, and research milestone payments. The company commercializes the BNT162b2 (Comirnaty) mRNA COVID-19 vaccine globally in collaboration with Pfizer, sharing gross profits and manufacturing responsibilities.
Growth strategy
BioNTech's stated goal is to become a multi-product oncology company by 2030. The plan rests on three groups of medicines: next-generation immunomodulators led by pumitamig, now in seven pivotal trials across lung, breast, colorectal and gastric cancer, and gotistobart; antibody-drug conjugates such as trastuzumab pamirtecan (HER2) and elfetabart drozuntecan (B7-H3), which has been given to more than 1,000 patients;
Competitive advantage
BioNTech's economic moat is grounded in its proprietary mRNA technology platform, structural immunology expertise, and specialized clinical manufacturing infrastructure.
Pfizer
How it makes money
Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies. Pfizer's commercial model operates across several primary therapeutic areas: Oncology, Vaccines, Internal Medicine, Hospital and Anti-Infectives, and Inflammation & Immunology.
Growth strategy
Pfizer's growth plan has three parts. Oncology: the $43 billion Seagen deal (closed December 2023) added Padcev, Adcetris, Tukysa and Tivdak, and Pfizer licensed 3SBio's PD-1xVEGF bispecific in 2025 and signed a 12-program cancer collaboration with Innovent Biologics in May 2026 ($650 million upfront, up to $10.5 billion total).
Competitive advantage
Pfizer's economic moat is rooted in its immense global clinical trial scale, unmatched commercial distribution infrastructure, and specialized aseptic vaccine manufacturing capabilities.
Questions about BioNTech vs Pfizer
Which company has higher revenue — BioNTech SE or Pfizer Inc.?
BioNTech SE had ~$3.2B (FY2025), while Pfizer Inc. had $62.6B (FY2025). By latest annual revenue, Pfizer Inc. is the larger business, with BioNTech SE showing a smaller revenue base.
What is the market cap of BioNTech SE vs Pfizer Inc.?
BioNTech SE's market capitalisation stands at $24.7B, while Pfizer Inc.'s is $160.3B. Pfizer Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to BioNTech SE.
How does revenue per employee compare for BioNTech SE and Pfizer Inc.?
BioNTech SE has $415k / employee in revenue per employee, while Pfizer Inc. has $834k / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.
How do BioNTech SE and Pfizer Inc. make money?
BioNTech SE and Pfizer Inc. generate revenue in fundamentally different ways. BioNTech SE: BioNTech SE operates a biotechnology commercialization and clinical development model, generating revenue through commercial vaccine sales, pharmaceutical partnership profit splits, licensing agreements, and research milestone payments. Pfizer Inc.: Pfizer Inc. is a research-based global biopharmaceutical company that discovers, develops, manufactures, and commercializes innovative prescription medicines, vaccines, and cellular therapies.
Which company is valued higher relative to revenue — BioNTech SE or Pfizer Inc.?
On a price-to-sales (P/S) basis, BioNTech SE trades at 7.6x P/S and Pfizer Inc. at 2.6x P/S. BioNTech SE commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Pfizer Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.
Is BioNTech SE bigger than Pfizer Inc.?
By last reported revenue, Pfizer Inc. ($62.6B (FY2025)) is the larger company compared to BioNTech SE (~$3.2B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.
Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the BioNTech vs Pfizer overview